



1

2

3

4

5

6

7

8

9

10

11 12 13

14

## Abstract

## Abelmoschus esculentus (okra) in regulation of hyperglycaemia in pre-diabetic and type 2 diabetic patients: Meta-analysis

|  | lo¹, Perpetua Modjadji², Saba Ghaffary <sup>:</sup> |
|--|---|
|--|---|

- <sup>1</sup> Department of Life and Consumer Sciences, College of Agriculture and Environmental Sciences, Florida Campus, University of South Africa, Roodepoort, South Africa; lebelol@unisa.ac.za
- Non-Communicable Disease Research Unit, South African Medical Research Council, Cape Town, South Africa; perpetua.modjadji@mrc.ac.za
- <sup>3</sup> Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; ghaffarys@tbzmed.ac.ir
- \* Correspondence: mokgak@unisa.ac.za; Tel.: +271147130000

Abstract: This study investigated the beneficial effects of okra on glycaemic control in pre-diabetes 15 and type 2 diabetes mellitus (T2D). MEDLINE and Scopus were searched for relevant studies. 16 Search followed an updated preferred reporting items for systematic review and meta-analysis. Col-17 lected data were analysed using Review Manager version 5.4, metaHun and reported as mean dif-18 ference and 95% confidence intervals (CI). Eight clinical studies, including 331 patients with pre-19 diabetes and T2D, were eligible. Our findings showed that okra treatment reduced the levels of 20 fasting blood glucose, mean difference (MD) = -14.70 mg/dL; 95% CI (-25.46, -3.95, p = 0.0074); I<sup>2</sup> = 21 34.6%, p = 0.17 compared to placebo. Glycated haemoglobin, however, did not differ significantly 22 between the groups: MD = 0.01%; 95%CI (-0.63, 0.65, p = 0.9767);  $I^2$  = 42%, p = 0.26. This study re-23 vealed an improved glycemic control following okra treatment in pre-diabetes and T2D patients. 24 The findings suggest that okra may be used as a supplemental dietary nutrient, especially in prediabetic and T2D patients due to its potential to regulate hyperglycaemia.

Keywords: okra; antioxidant; type 2 diabetes; inflammation; hyperglycaemia; pre-diabetes

28

34

35

36

37

38

Academic Editor: Firstname Lastname

https://doi.org/10.3390/xxxxx

Citation: Lastname, F.: Lastname, F.:

Lastname, F. Title. Med. Sci. Forum

Published: date

2023, 2, x.

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/license s/by/4.0/).

Author Contributions: Conceptualization, K.M.; methodology, K.M, and S.G.; software, K.M.; val-29 idation, K.M.,S.G.,PM., and S.L.L.; formal analysis, K.M.; investigation, K.M.; resources, K.M.; data 30 curation, K.M., and S.G.; writing-original draft preparation, K.M.; writing-review and editing, 31 K.M., S.G., P.M and S.L.L.; visualization, K.M., S.L.L.; supervision, S.L.L.; project administration, 32 K.M. All authors have read and agreed to the published version of the manuscript. 33

Funding: This work is based on the research supported in part by the Research Development Grants for nGAP Scholars (NGAP23022780506).

Institutional Review Board Statement: Not applicable Informed Consent Statement: Not applicable

Conflicts of Interest: The authors declare no conflict of interest.

25 26 27